AMLprofiler DNA Chip Launched in Europe

Acute myeloid leukemia is an agressive form of leukemia for which several genetic abnormalities are known that influence treatment and prognosis. Skyline Diagnostics, from the Netherlands, has launched the AMLprofiler, a diagnostic chip for acute myeloid leukemia. It combines nine different DNA assays, that previously had to be performed separately, into one chip. The device detects t(8;21), t(15;17) and inv(16), NPM1 mutation types A, B and D, as well as CEBPA double mutants. Also, expression levels of the 4 prognostic genes EVI1 BAALC, MN1 and ERG are determined. Test results are known within four days. Clinical studies are underway for certification by the US Food and Drug Administration (FDA). Also, Skyline Diagnostics is working on similar diagnostic tests for other forms of cancer, bringing personalized medicine just a bit closer to reality.
Press release: Dutch firm launches world’s first diagnostic chip that combines DNA technologies to rapidly classify AML patients…
Product page: AMLprofiler…